With its second pivotal Phase III showing an advantage for VBI Vaccines Inc.’s Sci-B-Vax over Engerix-B, GlaxoSmithKline PLC’s monovalent HBV vaccine, Cambridge, MA-based VBI is preparing for submission and market entry – but it faces a tougher challenge going up against Dynavax Technologies Corp.’s Heplisav-B.
VBI Is Ready To Take On HBV Vaccine Market
VBI’s Sci-B-Vac CONSTANT data firmly establishes the hepatitis B vaccine’s advantages over GSK’s longstanding Engerix-B, but it faces a tougher challenge with Heplisav-B from Dynavax.
